Details of the Drug-Related molecule(s) Interaction Atlas

SIB-1765F Drug Info

SIB 1765F; Pyridine, 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)-, (E)-2-butenedioate (1:1); Pyridine, 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)-, (2E)-2-butenedioate (1:1); C12H14N2.C4H4O4; AC1O5WWQ; SCHEMBL194945; SCHEMBL3099334; SIB 1508Y, fumarate, E-isomer; 179120-52-6; LS-173698

Cross-matching ID

PubChem CID

6442277

CAS Number

CAS 179120-52-6

TTD Drug ID

DM6MSKT

General Information of Drug (ID: DM6MSKT)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nicotinic acetylcholine receptor (nAChR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[2]
Cotinine	DMCEZ1B	Insecticide	N.A.	Approved	[3]
Pancuronium	DMB0VY8	Anaesthesia	9A78.6	Approved	[4]
Atracurium	DM42HXN	Anaesthesia	9A78.6	Approved	[4]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[5]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[6]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[7]
BMS-954561	DM7XV4R	Diabetic neuropathy	8C0Z	Phase 2	[8]
ASM-024	DM35S2I	Asthma	CA23	Phase 2	[9]
NIC-002	DMKLJMI	Nicotine dependence	6C4A.2	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nicotinic acetylcholine receptor (nAChR)	TTJSZTB	NOUNIPROTAC	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther. 1997 Jan;280(1):393-401.
2	Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
3	Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
4	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
5	Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
8	EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
9	Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
10	Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.